ATTO · NASDAQ · Biotechnology

Atento S.A.

$20.68
At close−0.78 (−3.63%)
Loading prices…

Profile

Atento S.A.ATTOHealth Care

Not reported.

Company facts

CEODimitrius Rogerio de Oliveira
ListedAug 5, 2026
ExchangeNASDAQ
HeadquartersSan Carlos, CA
CountryLuxembourg
Employees44
CIK0001606457
ISINLU2212224153

Key statistics

Market cap$890.7M
EPS (ttm)−$0.8774
P/E (ttm)−23.59
ROE-25.5%
P/B6.01
P/S0.00
Dividend yield
Beta

Year to date +21.6% · Average volume (30d) 510.4K

Analysts

No analyst consensus on record.

Earnings

Not reported.

Financial highlights

2 quartersQ1 FY25Q1 FY26
Revenue$0$0
Gross profit−$143.0K−$242.0K
Operating income−$16.1M−$20.0M
Net income−$15.2M−$18.7M
Diluted EPS−$0.40−$0.48
Gross margin
Operating margin

Balance sheet, Mar 31, 2026Cash & short-term investments $132.6M · Total debt $4.8M · Total assets $146.1M · Shareholders' equity $132.7M

Dividends

No dividends on record.

Ownership

Institutions Insiders 8.41%

Shares outstanding 43.03M · Float

Top shareholders13F · 13D/G · Form 4

HolderShares% outstandingFormFiled
venBio Global Strategic Fund IV, L.P. · 10 percent owner4.18M9.72%Form 4Aug 10, 2026
Alamar HoldCo, LLC · 10 percent owner3.23M7.50%Form 4Aug 5, 2026
Colin Walsh · director3.02M7.02%Form 4Aug 13, 2026
Redmile Group, LLC · 10 percent owner2.17M5.03%Form 4Aug 7, 2026
Deep Track Biotechnology Master Fund, Ltd. · 10 percent owner1.96M4.55%Form 4Aug 10, 2026

Insider tradesForm 4

DateInsiderRoleSharesAvg price
Aug 5, 2026Goldman Sachs Group Incother: Former 10% Owner+190,807$21.00
Aug 5, 2026Colin Walshdirector+190,807$21.00
Aug 6, 2026Colin Walshdirector+500,000$17.00
Aug 5, 2026Colin Walshdirector−105,607$21.28
Aug 6, 2026Goldman Sachs Group Incother: Former 10% Owner+500,000$17.00
View details

Peers

Not reported.